It has been announced that Pharmaceutical Product Development (PPD), LLC has renewed – for the fifth time – its contract with the Division of AIDS, National Institute of Allergy and Infectious Diseases and part of the National Institutes of Health. This contract extends to 2024, with the original contract being awarded in 1990.
The contract will support research into HIV and HIV co-infections, including vaccines work, prevention trials and therapeutic trials. Previous PPD contracts, lasting between 5–7 years, have involved monitoring for an average of 150 clinical studies per contract.
William Sharbaugh, chief operation officer of PPD, commented: “The extension of this contract will allow PPD to provide important comprehensive clinical site and study monitoring services to the NIH in some of the most pivotal and exciting directions in AIDS research…We are privileged to continue our collaborative relationship with the NIH, leveraging our considerable resources as one of the world’s largest CROs, while capitalizing on our in-depth knowledge of infectious diseases.”